Pay in 4 interest-free payments of $7.43 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
The test analyzes GIPR and FTO, and MC4R variants to reveal your predispositions in GLP-1 receptor sensitivity, dual-peptide response, baseline appetite regulation, and appetite-circuit signaling
Fair-skinned individuals may take slightly longer to see visible results
Genetic variations in your glucose-dependent insulinotropic peptide receptor (GIPR rs1800437), and appetite-regulating genes like FTO rs9939609 influence how strongly these medications suppress hunger
Peak anti-inflammatory benefit appears to coincide with the period of most active weight loss (months 3 through 9), though improvements persist as long as treatment continues
To overcome the short half-life and frequent subcutaneous administration of pramlintide, new amylin receptor agonists like cagrilintide have been developed
